جستجوی استاد راهنمای دانشگاهی

Soki Kashimaمشاهده پروفایل

استادیار

• Immunology
• Oncology
• Renal Cell Carcinoma
• +۵ مورد دیگر

Soki Kashima is a urologic surgeon and physician-scientist holding the rank of Assistant Professor at Akita University School of Medicine and Kyoto University Graduate School of Medicine. He completed his MD (2011) and PhD in Medicine (2020) from Akita University, with doctoral research on iPS cell-derived T-cell therapies for renal cell carcinoma under Prof. Hiroshi Kawamoto. At Yale School of Medicine, he serves as a Postdoctoral Associate in the Braun Lab, focusing on immunogenomic approaches to renal cancer immunotherapy. His research spans tumor microenvironment analysis, preclinical models, and clinical trials evaluating immunotherapies. Key contributions include demonstrating efficacy of T-cell therapies from induced pluripotent stem cells (iPS) in solid tumors and investigating biomarkers for immunotherapy response in renal cell carcinoma. Collaborations with David A. Braun and others have advanced understanding of T-cell phenotypes in checkpoint inhibitor efficacy. Notable awards include the 2024 ASCO Merit Award and Department of Defense Postdoctoral Fellowship. He has authored over 20 peer-reviewed publications in journals like Science Immunology , Cancer Medicine , and Urologic Clinics of North America . His work bridges basic science and clinical translation, particularly in optimizing immunotherapy strategies for renal cancers.

• Clinical Pharmacology
• Pharmacogenomics
• Pharmacometrics
• +۷ مورد دیگر

Associate Professor Sophie Stocker is affiliated with the Sydney Pharmacy School (University of Sydney), St Vincent’s Hospital (Honorary Senior Hospital Scientist in Clinical Pharmacology and Toxicology), and the Garvan Medical Research Institute . She also serves as an Adjunct Senior Lecturer at the St Vincent’s Clinical School, University of New South Wales. Research Focus: Her work spans clinical pharmacology , pharmacogenomics , pharmacometrics , and therapeutic drug monitoring (TDM) . Key areas include optimizing diabetes therapies through metformin pharmacogenomics, managing gout via urate-lowering strategies, and improving antimicrobial dosing in critically ill patients. Recent Trends: 2025 publications highlight her leadership in Bayesian model selection for antibiotic precision dosing Saliva-based TDM innovations Pharmacogenomic tools for allopurinol and clopidogrel Evaluating SGLT2 inhibitors in chronic kidney disease Global standards for antifungal TDM Scientific Awards: Victor Armstrong Young Investigator Award (2022) Emerging Leader Award (2020) CERTARA Young Investigator Award (2020) St Vincent's Rising Star (2018) ASCEPT Presidential Trainee Award (2013) Supervision: She mentors research students working on projects such as voriconazole TDM strategies , saliva-based tuberculosis monitoring , and CYP2C19-guided antiplatelet therapy . International Links: Collaborates with institutions in Germany (University of Hamburg) and New Zealand (University of Otago) on projects like model-informed precision dosing and gout management.

• Evidence Synthesis
• Nephrology
• Chronic Kidney Disease
• +۵ مورد دیگر

Dr. David Tunnicliffe is a Senior Research Fellow at the Sydney School of Public Health, The University of Sydney, based at the Centre for Kidney Research at The Children's Hospital at Westmead. He holds a PhD in medicine from the same university (2018). His research focuses on evidence synthesis, systematic reviews, and improving methods for clinical practice guidelines in kidney disease. He serves as Scientific Director of the CARI Guidelines (Australian/New Zealand clinical practice guidelines) and leads efforts in Cochrane Kidney and Transplant. Key roles include advancing living guidelines and addressing disparities in kidney care for Aboriginal and Torres Strait Islanders. Dr. Tunnicliffe also contributes to teaching, including coordinating the CEPI 5315 Introduction to Systematic Review unit in the Master of Clinical Epidemiology program. Education : PhD (Medicine), Sydney School of Public Health, The University of Sydney (2018). Research Interests : Quantitative and qualitative evidence synthesis for kidney disease Improving methods for systematic reviews and guideline development Dissemination of research findings to patients with kidney disease Recent Projects : Development of living guidelines for chronic kidney disease Clinical practice guidelines for Indigenous kidney care Meta-research on ethnicity reporting in kidney trials Awards : 2024 ANZSN Mid-Career Award (Clinical Science) 2024 Faculty of Medicine & Health Mid-Career Researcher Award Travel grants from ANZSN, ARS, and other organizations (2014–2017) Grants & Funding : NHMRC Emerging Leadership 1 Investigator Grant (2020) Department of Health & Aged Care grant for kidney disease guidelines (2021) Labs/Teams : Centre for Kidney Research, collaborating with international groups like Cochrane and KDIGO.

John Misasiمشاهده پروفایل

استادیار

• Virology
• Immunology
• Antibody Discovery
• +۴ مورد دیگر

Dr. John Misasi is an Assistant Professor at Boston University's Chobanian & Avedisian School of Medicine, specializing in Virology, Immunology, and Microbiology. He holds an MD from SUNY Upstate Medical University and a BS from Boston University. His research focuses on antibody discovery, viral pathogenesis, and structural biology. He has contributed to the development of FDA-approved Ebola therapies like mAb114 and leads studies on SARS-CoV-2, MPOX, and Lassa viruses. Dr. Misasi's lab investigates immune evasion mechanisms and antibody-mediated immunity at the National Emerging Infectious Disease Laboratory. He has been recognized with awards including the NIH Director’s Award and multiple NIAID Merit Awards. Education: MD: State University of New York Upstate Medical University BS: Boston University Research Interests: Dr. Misasi's work centers on understanding antibody mechanisms against high-containment pathogens. His lab uses virology, immunology, and structural biology tools to study viral entry pathways, neutralizing antibodies, and immune evasion strategies. Key areas include: Antibody engineering for SARS-CoV-2 and Ebola Vaccine design targeting viral glycoproteins Host-pathogen interactions in filoviruses Therapeutic antibody development Grants & Awards: National Institutes of Health Director’s Award (2020) NIAID Merit Award for Ebola Outbreak Response (2018) Vaccine Research Center Staff Recognition (2018) NIH UGSP and INRO Mentorship Programs (2019-2023) Labs & Teams: He leads the National Emerging Infectious Disease Laboratory (NEIDL) team focusing on high-containment pathogens. Collaborations include work at NIH Vaccine Research Center and Harvard Medical School.

Scott E. Schausمشاهده پروفایل

استاد

• Organic Chemistry
• Medicinal Chemistry
• Catalytic Synthesis
• +۳ مورد دیگر

Scott E. Schaus is a Professor of Organic and Medicinal Chemistry at Boston University. He leads the Schaus Group, focusing on enantioselective catalytic methodologies and biomedical research. His work spans development of novel synthetic techniques, including boronate catalysis and asymmetric Mannich reactions, as well as translational science targeting cancer and neglected tropical diseases. Collaborations with the Boston University Center for Molecular Discovery (CMD-BU) drive advancements in chemical library synthesis and drug discovery. Education: B.A. in Chemistry (Boston University, 1995; summa cum laude), Ph.D. in Organic Chemistry (Harvard University, 1999) Research: Specializes in catalytic asymmetric synthesis, natural product construction, and antiparasitic/anticancer drug development. Notable projects include liver cancer treatments with Prof. Ulla Hansen and work on Chagas disease. His lab has produced 20 Ph.D. graduates and 3 postdocs since 2001, with alumni in academia, pharmaceutical R&D, and industry. Current interests include expanding catalytic methodologies and applying chemical synthesis to biomedical challenges. The Schaus Group actively explores small molecule inhibitors, with a focus on LSF transcription factor pathways and antiviral agents.

Rasha Rezkمشاهده پروفایل

دانشگاهی

• Microfluidic Technologies
• Biomechanics
• Drug Delivery Systems
• +۵ مورد دیگر

Dr. Rasha Rezk is an Associate Lecturer in the Department of Biology at the University of York and a Royal Academy of Engineering Enterprise Fellow. Her research focuses on microfluidic technologies for biomedical applications, including mechanoporation systems for drug delivery and genome editing. She leads projects on blood stem cell biomechanics, cancer therapy innovations, and advanced therapeutics development. Rasha holds a PhD from the University of Cambridge and has been recognized as a 2024 graduate of the Creation Destruction Lab (Advanced Therapies). Her educational background includes a prestigious Independent Research Fellowship at Cambridge, complementing her academic career. Research interests emphasize leveraging mechanical forces to manipulate cellular behavior, with applications in leukemia treatment and non-viral genome editing. The ForCell platform, developed under her guidance, represents a breakthrough in mechanoporation for therapeutic delivery. Key projects include investigating biomechanical links to gene expression in blood cells and developing tuneable mechanical platforms for safe cargo delivery. Awards include the Royal Academy of Engineering Enterprise Fellowship and CDS Lab accreditation. Rasha actively supervises MSc projects in biomedical science and collaborates on grants for microfluidic technology advancements. Her work spans diverse fields from materials science to oncology, with a focus on translating lab innovations into clinical applications. Current efforts include refining the ForCell system for broader biomedical use and exploring plant synthetic biology applications of microfluidics.

• Medication Development
• Opioid Use Disorders
• Addiction Psychiatry
• +۳ مورد دیگر

Dr. Shanthi Mogali is an Assistant Professor of Psychiatry at Yale School of Medicine and currently serves as Chair of Psychiatry at Lawrence and Memorial Hospital and Westerly Hospital. Her research focuses on medication development and opioid self-administration studies to address opioid use disorders. She completed her MD at Meharry Medical College and a BA at Fisk University, with additional training in addiction psychiatry at Columbia University and general psychiatry at Emory University. Her work includes studies on the effects of medications like naltrexone, minocycline, and pioglitazone on opioid abuse potential and craving reduction. She has contributed to peer-reviewed publications on topics such as genetic influences on opioid response and pharmacological interventions for substance use disorders. Dr. Mogali’s clinical and research expertise lies in addiction psychiatry, with a strong emphasis on translational research to improve treatments for opioid dependence. She has held leadership roles in hospital departments and maintains an active role in clinical trials and academic publishing.

• Hematology
• Immunology
• Leukemia
• +۳ مورد دیگر

Kazuaki Kameda is a Research Fellow at the Yale School of Medicine, working in the laboratory of Dr. Andres Hidalgo. He holds an MD from Kyoto University (2009) and a PhD from Jichi Medical University (2022), focusing on the tumor microenvironment of natural killer cell leukemia. His research integrates immunology and hematology, particularly in the context of hematologic malignancies and transplantation medicine. Education & Training: MD, Kyoto University (2009) PhD, Jichi Medical University (2022) Research Interests: Dr. Kameda’s work spans tumor microenvironment dynamics, natural killer cell leukemia pathogenesis, and translational studies in hematopoietic stem cell transplantation. He investigates mechanisms of drug resistance, immune regulation in malignancies, and post-transplant complications. Publications Highlight Key Themes: His articles address conditioning regimens in transplantation, antibiotic management strategies, and metabolic pathways in leukemia. Recent work explores the hepatic niche’s role in NK cell leukemia proliferation and the clinical impact of physical function on transplant outcomes in older adults. Professional Background: Postdoctoral training at Yale follows residency/fellowships in internal medicine, infectious diseases, and hematology (Jichi Medical University). He is board-certified in hematology by the Japanese Society of Hematology (2016). Labs/Teams: Active contributor to Dr. Hidalgo’s lab, focusing on translational hematology and immunology.

• Neuro-Oncology
• Brain Tumors
• Clinical Neurology
• +۴ مورد دیگر

Sylvia Kurz, MD, PhD, is an Associate Professor of Neurology specializing in Neuro-Oncology at Yale School of Medicine. She leads patient care at the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center. Her research focuses on developing novel therapies and optimizing treatment protocols for brain tumors, particularly gliomas and meningiomas. Dr. Kurz holds dual degrees from Ludwig-Maximilians-University in Munich, Germany, and has completed advanced training at institutions including Massachusetts General Hospital and Perlmutter Cancer Center. Roles: Neuro-Oncologist, Associate Professor, Molecular Medicine Researcher Affiliations: Yale School of Medicine, Smilow Cancer Hospital, Chênevert Family Brain Tumor Center Education: MD and PhD: Ludwig-Maximilians-University, Munich Residency: University Hospitals Case Medical Center Fellowship: Massachusetts General Hospital/Dana-Farber Cancer Institute Dr. Kurz’s research emphasizes translational neuro-oncology, including radiopharmaceuticals, targeted therapies, and biomarker-guided treatment strategies. Her clinical work integrates cutting-edge diagnostics like SSTR2 PET imaging and molecular methylation profiling. She has pioneered initiatives like the DivINe Initiative to promote diversity in neuro-oncology leadership and co-developed the NEURO-MCBS clinical benefit scale for CNS tumor trials. Her clinical trials focus on therapies for glioblastoma, meningioma, and diffuse midline glioma (DMG), including ONC201 for H3 K27M-mutant tumors and LITT for glioblastoma recurrence. She also addresses care challenges such as venous thromboembolism management in brain tumor patients and caregiver psychosocial burdens. Dr. Kurz collaborates extensively with teams at Yale Cancer Center, the Molecular Tumor Board (TRACE initiative), and international neuro-oncology groups like NCOG. Her work spans from bench-to-bedside innovations in immunotherapy and precision medicine to improving patient-reported outcomes through digital health tools.

Shoib Siddiquiمشاهده پروفایل

مدرس ارشد

• Cancer Biology
• Immunology
• Glycobiology
• +۴ مورد دیگر

Dr. Shoib Siddiqui is a Senior Lecturer at the University of Hertfordshire's School of Life and Medical Sciences, specializing in cancer biology, immunology, and glycobiology. Previously, he held positions at the American University of Ras Al Khaimah and conducted postdoctoral research at UC San Diego under Prof. Ajit Varki. His research focuses on sialic acids, Siglecs, and microRNA mechanisms in cancer, Alzheimer’s, and sepsis. He earned his Ph.D. from ETH Zurich, investigating neuropilin-2 in skin cancer progression. Education: Ph.D. in Vascular Biology, Immunology, and Cancer Biology (ETH Zurich, 2009–2013) M.Sc. in Biotechnology (IIT Bombay, 2008) Research Focus: Dr. Siddiqui’s work explores cancer progression pathways, tumor biomarkers, and novel therapies. Key areas include Siglec-sialoglycan interactions, microRNA targeting, and drug repurposing for colorectal cancer. His recent projects involve developing RNAi therapeutics and inhibitors for Siglec-15. Projects: Fluralaner as a Colorectal Cancer Therapeutic (2026–2027) ADAMTS-7 Inhibition for Coronary Artery Disease (2022) UK-China Mycotoxin Reduction Alliance (2022–2023) Publications: Over 39 peer-reviewed articles in journals like Journal of Clinical Investigation , PNAS , and Blood , with a focus on oncology, glycobiology, and immunology. Recent trends emphasize Siglec-targeted therapies, microRNA networks, and drug repurposing strategies. Awards: No formal awards listed, but noted for impactful publications in high-impact journals. Advising & Grants: Served as Principal Investigator (PI) on RNAi therapeutics and Co-Investigator (CoI) on Siglec-15 and ADAMTS-7 projects. Collaborations span international institutions and cross-disciplinary teams. Labs/Teams: Active in the Biosciences Research Group and Centre for Research in Mechanisms of Disease and Drug Discovery at UH. Collaborates with global researchers in glycobiology and oncology.

• Weed Science
• Herbicide Resistance
• Agricultural Biology
• +۳ مورد دیگر

Dr Jenna Malone is a Grant-Funded Researcher (B) and Senior Mortlock Fellow at the University of Adelaide's School of Agriculture, Food and Wine, within the Faculty of Sciences, Engineering and Technology. Her research focuses on understanding and managing herbicide-resistant weeds, particularly investigating molecular and biochemical mechanisms of resistance. She is affiliated with the Weed Science Research Group and actively involved in projects addressing agricultural challenges caused by herbicide-resistant weeds. Her work emphasizes the evolution and inheritance of resistance mechanisms, such as glyphosate and ALS-inhibitor resistance, and their implications for sustainable weed management. Dr. Malone is eligible to supervise Honours, Masters, and PhD students, offering projects on weed management, herbicide resistance mechanisms, and herbicide-tolerant crops. Key research interests include genetic diversity in resistant weed populations, gene amplification, and mutation-driven resistance. Her contributions bridge molecular biology and applied agriculture, aiming to develop strategies to combat herbicide resistance and improve agricultural productivity. Dr. Malone's research also explores seed dormancy and environmental stress impacts on weeds, contributing to integrated pest management approaches. She collaborates across disciplines to address agricultural sustainability through innovative solutions.

• Virology
• HIV Research
• Vaccine Development
• +۳ مورد دیگر

Stephen Dewhurst, Ph.D., is Vice President for Research and Chief Research Officer at the University of Rochester (UR) and Vice Dean for Research at the UR School of Medicine and Dentistry (SMD). He holds a professorship in the Department of Microbiology and Immunology (SMD). His administrative roles include former department chair (2009–2021), SMD Senior Associate Dean for Basic Research (2007–2009), and codirector of UR’s Center for AIDS Research (2008–2020). Dr. Dewhurst’s research focuses on virology, with 30+ years’ experience including HIV neuropathogenesis, vaccine development, and innate immune responses. He leads NIH-funded programs in graduate education and Deaf postdoctoral training. His mentorship has guided 29 Ph.D. students, 16 postdoctoral fellows, and >100 undergraduates, earning awards like the William H. Riker Award (2008) for graduate education. Key scientific contributions include HIV humanized mouse models, antiviral therapeutics, and MLK inhibitors for neuroinflammation. His patents span viral vectors, integrin-binding monobodies, and influenza vaccines. Awards include membership on NIH study sections (e.g., HIV Immunopathogenesis) and editorial roles in virology journals.

• Immunology
• Vaccine Biology
• Cytokine Research
• +۳ مورد دیگر

Tim R. Mosmann is a Professor and Director of the Human Immunology Center at the University of Rochester, leading the David H. Smith Center for Vaccine Biology and Immunology. He holds the Michael and Angela Pichichero Director's Endowed Chair. His academic journey includes B.S. degrees in Chemistry, Physiology, and Microbiology from the University of Natal and Rhodes University in South Africa, followed by a Ph.D. in Microbiology from the University of British Columbia. After postdoctoral training at the University of Toronto and Glasgow University, he held academic positions at the University of Alberta before joining the University of Rochester in 1998. Dr. Mosmann is renowned for discovering the Th1/Th2 T cell subsets, a pivotal contribution to understanding immune regulation and vaccine design. His research focuses on cytokine networks, T cell differentiation, and immune responses to infections and vaccines. He has authored over 250 publications and holds patents on technologies for immune response detection, including arrayed sensor systems for influenza and HPV immunity analysis. His awards include the Novartis Prize for Basic Immunology, multiple Pillars of Immunology recognitions, and election to the Royal Society of Canada. His work bridges immunology, vaccinology, and clinical translation, emphasizing the role of T cell subsets in health and disease. Collaborations span academia and industry, advancing methodologies in flow cytometry and automated data analysis.

Xia Liuمشاهده پروفایل

استادیار

• Cancer Biology
• Breast Cancer Metastasis
• Neutrophil Biology
• +۳ مورد دیگر

Xia Liu, PhD, is an Assistant Professor in the Department of Toxicology and Cancer Biology at the University of Kentucky. Her research focuses on understanding mechanisms of breast cancer metastasis, particularly the roles of neutrophils, tumor-associated inflammation, and liquid biomarker discovery. She co-leads projects on immune checkpoint inhibitors in triple-negative breast cancer (TNBC) and tumor-induced granulopoiesis. Dr. Liu earned her PhD in Cancer Biology from Peking Union Medical College & Chinese Academy of Medical Sciences, China. Her lab's work integrates molecular biology, immunology, and translational approaches to identify therapeutic targets and improve cancer treatment efficacy. Key research areas include: Neutrophil biology in cancer progression CD44-mediated tumor cell clustering ICAM1-suPAR-CD11b axis as a therapeutic target Machine learning applications in cancer biomarker discovery Her lab has published in high-impact journals like Molecular Cancer , Nature Communications , and Cancer Discovery . She collaborates with institutions globally to advance metastasis research and clinical translation. Dr. Liu's lab is located at Research Building 2, Room 424, and maintains an active research website at xialiulab.com .

Tuba Esatbeyogluمشاهده پروفایل

استاد

• Molecular Food Chemistry
• Food Development
• Secondary Plant Metabolites
• +۱۲ مورد دیگر

Prof. Dr. Tuba Esatbeyoglu is a full Professor of Molecular Food Chemistry and Development and serves as the Executive Director of the Institute of Food Science and Human Nutrition at Leibniz University Hannover, within the Faculty of Natural Sciences. She leads research in food chemistry, quality, and safety, with a focus on bioactive compounds and sustainable food innovation. Research Interests: Her work centers on secondary plant metabolites, food by-product utilization, HPLC method development, proanthocyanidin chemistry, food stability, authenticity markers, and in vitro biological activity and toxicity. She investigates the bioaccessibility and sensory properties of functional foods, contributing significantly to food quality and safety science. Publication Trends: Her recent publications reflect a strong focus on polyphenols, encapsulation technologies, food waste valorization, and analytical method development. She frequently explores the health impacts of plant extracts, liver protection, and sustainable food systems, often employing in vitro and animal models. Scientific Awards: Georg Forster Research Award (Alexander von Humboldt Foundation, 2022) Poster Prize, Brunel University (2014) Danone Nutrition for Health Institute Scholarships (2013, 2014) Rochow Family Trust Scholarship (2012) DGQ Young Scientist Award (2011) Award for Outstanding Academic Achievements in Food Chemistry (2006) Advising and Grants: While specific students are not listed, she supervises research in food science and has served on examination boards. She has led projects including a genetic engineering S1 facility and holds permissions under the Infection Protection Act. She has been involved in reviewing for major funding bodies including DFG, DAAD, and the Alexander von Humboldt Foundation. Labs and Teams: She heads the Molecular Food Chemistry and Development research group at the Institute of Food Science and Human Nutrition. She is active in national and international scientific networks, including DECHEMA, GDCh, DGE, IFT, and FEI’s Scientific Advisory Board, and contributes to standardization efforts via DIN.